- Home
- IROQ vs IKNA Comparison
IROQ vs IKNA Comparison
Compare IROQ & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROQ
- IKNA
- Stock Information
- Founded
- IROQ 1883
- IKNA 2016
- Country
- IROQ United States
- IKNA United States
- Employees
- IROQ N/A
- IKNA N/A
- Industry
- IROQ Savings Institutions
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- IROQ Finance
- IKNA Health Care
- Exchange
- IROQ Nasdaq
- IKNA Nasdaq
- Market Cap
- IROQ 78.9M
- IKNA 64.7M
- IPO Year
- IROQ 2011
- IKNA 2021
- Fundamental
- Price
- IROQ $23.25
- IKNA $1.31
- Analyst Decision
- IROQ
- IKNA Buy
- Analyst Count
- IROQ 0
- IKNA 2
- Target Price
- IROQ N/A
- IKNA $3.00
- AVG Volume (30 Days)
- IROQ 3.6K
- IKNA 84.9K
- Earning Date
- IROQ 04-29-2025
- IKNA 03-06-2025
- Dividend Yield
- IROQ 1.73%
- IKNA N/A
- EPS Growth
- IROQ 56.77
- IKNA N/A
- EPS
- IROQ 0.95
- IKNA N/A
- Revenue
- IROQ $24,226,000.00
- IKNA N/A
- Revenue This Year
- IROQ N/A
- IKNA N/A
- Revenue Next Year
- IROQ N/A
- IKNA N/A
- P/E Ratio
- IROQ $24.30
- IKNA N/A
- Revenue Growth
- IROQ 8.37
- IKNA N/A
- 52 Week Low
- IROQ $14.85
- IKNA $1.22
- 52 Week High
- IROQ $25.76
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- IROQ 37.84
- IKNA 41.32
- Support Level
- IROQ $23.55
- IKNA $1.27
- Resistance Level
- IROQ $24.90
- IKNA $1.43
- Average True Range (ATR)
- IROQ 0.60
- IKNA 0.06
- MACD
- IROQ -0.12
- IKNA 0.00
- Stochastic Oscillator
- IROQ 0.00
- IKNA 27.91
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.